Galectin-9:胶质瘤中负向调控免疫反应的预测性生物标志物
本研究基于GSE 16011、CGGA和TCGA数据集的1292例胶质瘤患者,分析Galectin-9(GAL-9)表达与临床及分子特征的关系。结果显示GAL-9高表达与恶性肿瘤发生倾向及免疫反应功能相关,且与所有级别胶质瘤的总生存期负相关,是预后不良的独立指标。GAL-9在调控胶质瘤免疫抑制特征中起关键作用,有望成为免疫治疗靶点。
要点
- GAL-9高表达与胶质瘤恶性程度及免疫反应功能密切相关。
- GAL-9高表达与所有级别胶质瘤(含高级别)总生存期负相关。
- GAL-9高表达是胶质瘤预后不良的独立指标。
核心结论
- GAL-9在调控胶质瘤免疫抑制特征中起关键作用,是预后不良的独立指标及潜在免疫治疗靶点。
研究设计与样本
- 回顾性分析GSE 16011芯片集、中国胶质瘤基因组图谱(CGGA)和癌症基因组图谱(TCGA)数据集中共1292例胶质瘤患者。
- 采用Kaplan-Meier分析探讨GAL-9的预后价值,使用Graphpad软件和R语言进行统计分析。
主要发现
- GAL-9表达与主要临床和分子特征高度相关,高表达患者更易发生恶性肿瘤。
- 基因本体(GO)分析显示GAL-9表达与胶质瘤免疫反应功能密切相关。
- Kaplan-Meier分析显示GAL-9表达与所有级别胶质瘤(包括高级别胶质瘤)的总生存期负相关。
- GAL-9高表达是预后不良的独立指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioma is the most frequent primary brain tumor. Immunotherapy is one of the most promising therapeutic approaches for gliomas. T cell immunoglobulin domain and mucin domain-3 can induce the malignancy of gliomas. The function of galectin-9 (GAL-9), as one of the ligands of T cell immunoglobulin domain and mucin domain-3, in glioma has remained elusive. The aim of this study was to characterize the expression of GAL-9 in patients with glioma. METHODS: This study enrolled 1292 patients with glioma from the GSE 16011 array set, the Chinese Glioma Genome Atlas, and The Cancer Genome Atlas datasets. Kaplan-Meier analysis was undertaken to explore the prognostic value of GAL-9. Graphpad software and R language were used for statistical analysis. RESULTS: Expression of GAL-9 was highly correlated with major clinical and molecular features. Patients with high expression of GAL-9 were more susceptible to development of malignant tumors. Gene Ontology analysis revealed that expression of GAL-9 was closely associated with function of immune response in glioma. Clinically, the results of Kaplan-Meier analysis showed that expression of GAL-9 was negatively associated with overall survival in all grades of glioma including high-grade gliomas. High expression of GAL-9 was an independent indicator of poor prognosis. CONCLUSIONS: Our results highlight the pivotal role of GAL-9 in regulation of immune suppressive features of gliomas and indicate that GAL-9 is a promising target for cancer immunotherapy and may lead to development of further therapies.
引用
- Liang T, Wang X, Wang F, et al. Galectin-9: A Predictive Biomarker Negatively Regulating Immune Response in Glioma Patients. World Neurosurg. 2019. PMID: 31470166. doi:10.1016/j.wneu.2019.08.117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。